Listed equity
Glenmark Pharmaceuticals
ग्लेनमार्क · ગ્લેનમાર્ક
₹2192.50▲₹14.85(+0.68%)
EOD close · 3 Jul 2026
consolidationdistribution -33
Range-bound — awaiting direction.
52W low ₹1767.1052W high ₹2471.05
Now at 60% of its 52-week range
Long-term returns
1Y
+23.9%
3Y
+235.1%
5Y
+233.6%
10Y
+176.1%
Phase indicator
consolidation-11.3% from 52w high
Range-bound — awaiting direction.
1M
+1.7%
3M
+5.5%
1Y
+23.9%
Delivery conviction
distributionscore -33
Delivery vs 20-day avg0.61x
Lifetime story
Glenmark Pharmaceuticals is up 47563.0% from its lifetime low of ₹4.60 on 17 Aug 2001. ₹10,000 invested then would be worth ₹47,66,304 today (28.1% CAGR over 24.9 years). Lifetime high of ₹2471.05 was set on 29 Apr 2026 (currently -11.3% below).
Fundamentals
Standalone vs consolidated — most retail products show only one. Consolidated includes subsidiary contribution.
727% cheaper than industry(Industry P/E 49.5)
| Standalone | Consolidated | |
|---|---|---|
| P/E (TTM)subs material | -310.37 | 45.79 |
| P/Bsubs material | 2.59 | 5.94 |
| Price / Cash flowsubs material | 1782.14 | 32.22 |
| Dividend yield | 0.23% | 0.23% |
| Book value / sharesubs material | 855.79 ₹ | 372.50 ₹ |
| EPS (TTM)subs material | -7.12 ₹ | 48.26 ₹ |
Market cap
₹62.4K Cr
52W high
₹2471.05
29 Apr 2026
52W low
₹1767.10
4 Jul 2025
Returns ladder
1W
+2.6%
1M
+1.7%
3M
+5.5%
6M
+7.0%
YTD
+8.5%
1Y
+23.9%
3Y
+235.1%
5Y
+233.6%
10Y
+176.1%
Since listing
+10000.0%